Showing results (691-700 of 705) with videos related to
Sort By:
Pageof 71
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Non-Hodgkin's lymphomas, version 4.2014Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyRanjana H Advani, Christopher R Kelsey, Philippe Armand, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 6, 2020
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 3, 2016
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017William G Wierda, Andrew D Zelenetz, Leo I Gordon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.Blood Advances|April 9, 2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter StudyNikhil Yegya-Raman, John P Plastaras, Christopher M Wright, et al.Pageof 71